Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice.

Parkinson's disease is a neurodegenerative disorder that affects mainly the nigrostriatal dopaminergic system in humans. Several propositions have been put forward to explain the cellular and molecular pathobiology of this syndrome. Initial attempts were made through the use of various agents to manipulate the deleterious effects of toxins that destroy dopaminergic cells both in vitro and in vivo. These studies led to the idea that oxidative stress is an important factor in killing these cells. More recent attempts have made use of genetically modified mice to eliminate or over-express genes of interest. These experiments have suggested that the destruction of dopaminergic cells might be the result of the convergence of dependent and independent molecular pathways and that trigger cellular events might lead to the demise of these dopaminergic cells.

[1]  L. Seiden,et al.  Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.

[2]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[3]  G. C. Wagner,et al.  Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.

[4]  H Ujike,et al.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Sklar,et al.  Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. O'dell,et al.  MK‐801 protection against methamphetamine‐induced striatal dopamine terminal injury is associated with attenuated dopamine overflow , 1992, Synapse.

[7]  J. Bennett,et al.  Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[8]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[9]  J. Cadet,et al.  The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynatic nigrostriatal markers in the rat , 1992, Brain Research.

[10]  W Slikker,et al.  MPTP‐induced oxidative stress and neurotoxicity are age‐dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels , 1994, Synapse.

[11]  W. Nicklas,et al.  Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. , 1989, Science.

[12]  J. Cadet,et al.  Melatonin attenuates methamphetamine‐induced toxic effects on dopamine and serotonin terminals in mouse brain , 1998, Synapse.

[13]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[14]  S. Appel,et al.  Scientific approaches to clinical neurology , 1977 .

[15]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[16]  C. Epstein,et al.  Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic Mice , 1994, Journal of neurochemistry.

[17]  S. Snyder,et al.  Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. , 1994, Science.

[18]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[20]  S. O'dell,et al.  Excitotoxic striatal lesions protect against subsequent methamphetamine-induced dopamine depletions. , 1994, The Journal of pharmacology and experimental therapeutics.

[21]  M. Mattson,et al.  Evidence for Synaptic Apoptosis , 1998, Experimental Neurology.

[22]  G. Cohen Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. , 1987, Advances in neurology.

[23]  Syed F. Ali,et al.  The Neuronal Nitric Oxide Synthase Inhibitor, 7‐Nitroindazole, Protects Against Methamphetamine‐Induced Neurotoxicity In Vivo , 1996, Journal of neurochemistry.

[24]  R. DePinho,et al.  p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens , 1994, Nature.

[25]  J. Cadet,et al.  p53‐Knockout Mice Are Protected Against the Long‐Term Effects of Methamphetamine on Dopaminergic Terminals and Cell Bodies , 1997, Journal of neurochemistry.

[26]  D Giulian,et al.  Characterization of ameboid microglia isolated from developing mammalian brain , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[28]  S. Daniel,et al.  Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.

[29]  J. Cadet,et al.  Invited Review Free radicals and the pathobiology of brain dopamine systems , 1998, Neurochemistry International.

[30]  J. Cadet,et al.  Nitric Oxide Is a Mediator of Methamphetamine (METH)‐Induced Neurotoxicity , 1996, Annals of the New York Academy of Sciences.

[31]  J. Cadet,et al.  Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats , 1991, Brain Research Bulletin.

[32]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[33]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[34]  I. Kopin MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. , 1987, Environmental health perspectives.

[35]  A. Fornace,et al.  Induction of Cellular p53 Activity by DNA-Damaging Agents and Growth Arrest , 1993, Molecular and cellular biology.

[36]  J. Cadet,et al.  Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice , 1998, Neuroscience.

[37]  J. Cadet,et al.  Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain , 1989, Brain Research.

[38]  J. Langston,et al.  Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment , 1986, Brain Research.

[39]  C. Miller,et al.  Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. , 1991, Molecular and chemical neuropathology.

[40]  J. Cadet,et al.  Methamphetamine‐Induced Changes in Antioxidant Enzymes and Lipid Peroxidation in Copper/Zinc‐Superoxide Dismutase Transgenic Mice , 1998, Annals of the New York Academy of Sciences.

[41]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[42]  T. Montine,et al.  Enhanced N‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Toxicity in Mice Deficient in CuZn‐Superoxide Dismutase or Glutathione Peroxidase , 2000, Journal of neuropathology and experimental neurology.

[43]  J. Cardelli The Abundance of Heavy Elements in Interstellar Gas , 1994, Science.

[44]  D. Guastella,et al.  Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Marsden,et al.  Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.

[46]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[47]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[48]  M. V. Van Woert,et al.  Brain peroxidase and catalase in Parkinson disease. , 1975, Archives of neurology.

[49]  J. Penney,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2 , 1998, The Journal of Neuroscience.

[50]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[51]  C. Mytilineou,et al.  Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. , 1976, The Journal of pharmacology and experimental therapeutics.

[52]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[53]  P. Huang,et al.  Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. , 1998, The Journal of pharmacology and experimental therapeutics.

[54]  K. Jellinger,et al.  Iron and ferritin in substantia nigra in Parkinson's disease. , 1993, Advances in neurology.

[55]  S. Kish,et al.  Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.

[56]  D. Murphy,et al.  Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. , 1994, Journal of neural transmission. Supplementum.

[57]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[58]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[59]  C. Epstein,et al.  Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice , 1996, Brain Research.

[60]  T. Dawson,et al.  Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[61]  J. Langston,et al.  MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. , 1984, Acta neurologica Scandinavica. Supplementum.

[62]  G. Uhl,et al.  Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. , 1999, Brain research. Molecular brain research.

[63]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[64]  Cytotoxicity of microglia , 1993 .

[65]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[66]  S. Chakraborti,et al.  Oxidant, mitochondria and calcium: an overview. , 1999, Cellular signalling.

[67]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[68]  D. Sulzer,et al.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  N. Sone,et al.  Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and 1‐Methyl‐4‐Phenylpyridinium Ion on Activities of the Enzymes in the Electron Transport System in Mouse Brain , 1987, Journal of neurochemistry.

[70]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[71]  S Fahn,et al.  Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. , 1971, Journal of the neurological sciences.

[72]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[73]  G. Breese,et al.  Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. , 1970, The Journal of pharmacology and experimental therapeutics.

[74]  C. Marsden,et al.  Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .

[75]  M. Fritsche,et al.  Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. , 1993, Oncogene.

[76]  E. Melamed,et al.  Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[77]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[78]  D. Hinshaw,et al.  Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. , 1986, The Journal of clinical investigation.

[79]  M. Zigmond,et al.  Estimating Hydroxyl Radical Content in Rat Brain Using Systemic and Intraventricular Salicylate: Impact of Methamphetamine , 1995, Journal of neurochemistry.

[80]  N. Hay,et al.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.

[81]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[82]  A. Schapira,et al.  Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.

[83]  J. Cadet,et al.  Methamphetamine induces apoptosis in immortalized neural cells: Protection by the Proto‐Oncogene, bcl‐2 , 1997, Synapse.

[84]  R. Duvoisin,et al.  Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.

[85]  M. Lovett,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[86]  J. Cadet,et al.  Methamphetamine administration causes overexpression of nNOS in the mouse striatum , 1999, Brain Research.

[87]  G. Cohen,et al.  The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.

[88]  Syed F. Ali,et al.  Effects of 7‐Nitroindazole, an NOS Inhibitor on Methamphetamine‐Induced Dopaminergic and Serotonergic Neurotoxicity in Mice a , 1998, Annals of the New York Academy of Sciences.

[89]  M. Beal,et al.  Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity , 1998, Neurobiology of Disease.

[90]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[91]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[92]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[93]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[94]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[95]  J. Cadet,et al.  Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.

[96]  B. Yamamoto,et al.  Methamphetamine‐induced neurotoxicity: Roles for glutamate and dopamine efflux , 1994, Synapse.